How the WHO Prequalification Programme Shapes Regulatory Affairs Work in Global Health

Introduction

Most regulatory affairs careers are built around a handful of familiar authorities: FDA, EMA, maybe Health Canada or the UK's MHRA. The World Health Organization's Prequalification Programme, usually shortened to WHO PQ, rarely gets the same attention in career conversations, yet it governs a genuinely distinct and consequential slice of regulatory affairs work, one that sits closer to global public health than to a typical national marketing authorization and that creates its own specific hiring demand at the companies that supply medicines, vaccines, and diagnostics into global health markets.

Understanding what WHO PQ actually is, and is not, matters for anyone whose company sells into markets supported by UN agencies, Gavi, or the Global Fund, and for regulatory professionals curious about a career path that looks noticeably different from conventional FDA or EMA-focused work.

What the WHO Prequalification Programme Actually Is

WHO PQ is not a regulatory authority, and prequalification is not the same thing as a national marketing authorization. It is a technical assessment process run by WHO that evaluates the quality, safety, and efficacy of priority health products, medicines, vaccines, in vitro diagnostics, and vector control products, intended primarily for procurement by United Nations agencies, Gavi, the Global Fund, and national governments in countries that rely on WHO's assessment as part of their own procurement and registration decisions.

In practice, this means a product can hold WHO prequalification and still need separate national marketing authorization in the countries where it is actually distributed, though WHO PQ is frequently relied upon, and sometimes explicitly referenced in national legislation, as a basis for accelerated or simplified national registration in countries with more limited regulatory review capacity of their own. The programme functions as a form of quality assurance infrastructure for global health procurement, rather than as a replacement for national regulatory systems.

The Dossier and Inspection Work Involved

Pursuing WHO prequalification involves submitting a dossier broadly similar in structure to a Common Technical Document submission used for stringent national regulatory authorities, covering quality, safety, and efficacy data, but adapted to WHO's specific technical requirements and assessment procedures. Manufacturing sites are subject to WHO-led or WHO-recognized inspections against good manufacturing practice expectations, and site inspection findings are a frequent source of delay or rejection, which makes inspection readiness as central to this work as it is to any FDA or EMA-facing regulatory function.

A regulatory affairs team supporting a WHO PQ submission needs to manage dossier compilation, respond to WHO's technical queries over what is often a multi-round assessment process, and coordinate site readiness across manufacturing facilities that may be located in multiple countries, sometimes including facilities that have never been inspected by a stringent regulatory authority before and need to be brought up to that standard specifically for the WHO assessment.

The Collaborative Registration Procedure

One of the more practically important mechanisms tied to WHO PQ is the Collaborative Registration Procedure, sometimes abbreviated CRP, through which WHO shares its assessment outcome, with the applicant's consent, with national regulatory authorities in countries where the product is intended to be registered. This is designed to speed up subsequent national approvals by letting a national authority rely substantially on WHO's completed technical assessment rather than repeating the full review independently.

For a regulatory affairs team, working within the Collaborative Registration Procedure means coordinating timing and documentation across WHO and multiple national authorities simultaneously, understanding which countries participate in the mechanism for a given product category, and managing the practical reality that even a collaborative, accelerated national review still involves its own correspondence, queries, and local requirements that do not disappear simply because WHO has already completed its assessment.

How This Interacts With Stringent Regulatory Authority Approval

Many companies pursuing WHO PQ already hold, or are simultaneously pursuing, approval from what WHO refers to as a stringent regulatory authority, a list that includes FDA, EMA, and a defined set of other mature national and regional regulators. Prior approval from a stringent regulatory authority can streamline the WHO PQ assessment through reliance procedures that let WHO draw on that authority's completed review rather than starting entirely from scratch.

This means regulatory affairs professionals working on WHO PQ submissions often need to think across two parallel regulatory tracks at once, structuring a company's overall regulatory strategy so that a stringent authority approval and a WHO PQ submission reinforce rather than duplicate each other's work, and sequencing submissions in a way that captures the efficiency these reliance mechanisms are designed to offer.

Why This Creates Distinct Hiring Demand

Companies whose products are genuinely central to global health procurement, vaccine manufacturers, generic and essential medicine producers, and diagnostics companies supplying programs funded by the Global Fund or Gavi, need regulatory affairs staff who understand WHO PQ's specific dossier expectations, its inspection culture, and the practicalities of the Collaborative Registration Procedure, none of which is automatically covered by strong FDA or EMA experience alone. This is a genuinely specialized body of procedural knowledge, and it is in comparatively short supply relative to the number of professionals experienced with conventional stringent authority submissions.

The work also tends to involve more hands-on coordination with manufacturing sites in a wider range of countries, including facilities in low- and middle-income countries working toward international manufacturing quality standards for the first time, which calls for a particular kind of patient, detail-oriented project management alongside the core regulatory writing and strategy skills.

There is also a steady, if smaller, stream of demand tied to companies expanding manufacturing capacity into new regions specifically to support global health supply, a vaccine manufacturer opening a second production site to meet Gavi-funded demand, for example, where regulatory affairs staff are needed early to help design the manufacturing and quality systems with WHO PQ expectations already in mind, rather than retrofitting a facility built without that end goal in view.

Where This Work Tends to Sit

WHO PQ expertise is most commonly found at multinational vaccine manufacturers, generic drug producers with a significant global health or humanitarian supply business, diagnostics companies whose products are used in HIV, tuberculosis, or malaria programs, and, less commonly, within regulatory affairs consultancies that support smaller manufacturers through the prequalification process. It also appears, somewhat differently structured, within multilateral organizations and certain non-governmental global health organizations that work alongside manufacturers on access-oriented regulatory strategy, though those roles tend to sit closer to policy and program management than to a conventional industry regulatory affairs position.

Skills and Background That Matter

Direct prior experience with a WHO PQ submission is the strongest credential, but it is not the only path in. Experience with CTD-format submissions to a stringent regulatory authority, genuine comfort with GMP inspection readiness across multiple international sites, and some exposure to the specific technical and public health considerations that shape WHO's priority product lists all transfer meaningfully. A track record of coordinating complex, multi-country regulatory timelines, even outside the WHO PQ context specifically, is also a reasonable signal that someone can manage the particular logistical complexity this work involves.

Language and cultural fluency across the countries where manufacturing sites and national regulatory partners are located can matter more here than in conventional FDA or EMA-focused roles, simply because so much of the coordination work involves manufacturing facilities and national authorities outside the handful of jurisdictions most regulatory affairs careers are built around. Patience with a process that genuinely moves on WHO's own timeline, rather than a predictable statutory review clock, is also a real and underrated part of succeeding in this work.

What a Typical Project Actually Looks Like

A WHO PQ project for a new vaccine or medicine commonly spans well over a year from initial dossier submission to final prequalification listing, and it rarely proceeds in a straight line. A first assessment round frequently produces a substantial list of technical queries covering manufacturing process detail, stability data, or quality control methodology, each of which needs a documented response before the file moves forward. In parallel, a site inspection may surface findings that require corrective action and follow-up evidence before WHO is satisfied the manufacturing facility meets expectations, work that often falls jointly to regulatory affairs and quality teams working closely together rather than to regulatory affairs alone.

Because the stakes often include real humanitarian consequences, a vaccine or essential medicine delayed from a procurement list can mean a delayed public health program, the work tends to carry a different emotional weight than a typical commercial submission, even though the technical mechanics share a great deal with conventional regulatory affairs practice.

Conclusion

WHO prequalification sits a little outside the regulatory affairs mainstream, overshadowed in most career conversations by FDA and EMA work, but it governs a genuinely important and distinct slice of how medicines, vaccines, and diagnostics reach some of the markets that depend on them most. For regulatory professionals with an interest in global health, and for companies whose products matter to international procurement programs, this is a body of specialized procedural knowledge worth building deliberately, not a footnote to conventional regulatory affairs work.

Frequently Asked Questions